Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.47 |
| ▸ | HTR2B | P41595 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30873752 | 0.90 | TACR1 (0.43) | HTR2CHTR2BHTR2ANR1H2PARP1 | |
| SCHEMBL30502301 | 0.89 | HTR2C (0.44) | HTR2CHTR2BHTR2ANR1H2PARP1 | |
| SCHEMBL31556646 | 0.88 | NR1H2 (0.53) | HTR2CHTR2BHTR2ANR1H2PARP1 | |
| SCHEMBL873237 | 0.87 | RAD52 (0.41) | HTR2CHTR2BHTR2ATERTNR1H2 | |
| SCHEMBL27887751 | 0.85 | NR1H2 (0.38) | HTR2CHTR2BHTR2ATERTNR1H2 | |
| SCHEMBL27904545 | 0.85 | NR1H2 (0.38) | HTR2CHTR2BHTR2ATERTNR1H2 | |
| SCHEMBL27747418 | 0.85 | NR1H2 (0.38) | HTR2CHTR2BHTR2ATERTNR1H2 | |
| SCHEMBL22285173 | 0.85 | NR1H2 (0.49) | NR1H2PARP1MAPK1NR1H3GPR119 | |
| SCHEMBL874416 | 0.85 | NR1H2 (0.49) | NR1H2PARP1MAPK1NR1H3GPR119 | |
| SCHEMBL4325057 | 0.85 | NR1H2 (0.49) | NR1H2PARP1MAPK1NR1H3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768806-A | Substituted 1,2, 3-triazole compound, preparation method thereof and application thereof in preventing and treating plant diseases | 中国农业大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-115991679-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115873022-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-110678472-B | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-110678472-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯治疗公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-101754761-B | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS INC | 2014-06-18 | — | — | CN | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | HTR2C 149/4885HTR2B 189/4885HTR2A 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.